Sugi Predict

Sugi Predict / Compounds / SCHEMBL3410263

SCHEMBL3410263

SCHEMBL3410263

CCCCC/C=C\C/C=C\CCCCCCCC(=O)O[C@@H](CO)COP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.81

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.81
▸ SMN1; SMN2 Q16637 1/20 0.69
▸ NR5A2 O00482 1/20 0.69
▸ NR5A1 Q13285 1/20 0.69
▸ S1PR1 P21453 1/20 0.68
▸ RECQL P46063 1/20 0.65
▸ MAPT P10636 2/20 0.61
▸ FAAH O00519 1/20 0.56
▸ HPGD P15428 1/20 0.56
▸ CNR1 P21554 1/20 0.56
▸ CNR2 P34972 1/20 0.56
▸ PRKCE Q02156 1/20 0.56
▸ PRKCQ Q04759 1/20 0.56
▸ PRKCD Q05655 1/20 0.56
▸ PRKCA P17252 1/20 0.56
▸ GPR55 Q9Y2T6 2/20 0.55
▸ SELP P16109 1/20 0.55
▸ DAGLA Q9Y4D2 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15689715 1.00 ALDH1A1 (0.81) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL4178822 0.99 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL3409780 0.97 ALDH1A1 (0.83) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL753300 0.97 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL3403745 0.97 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL3406019 0.97 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL3405833 0.97 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL3410573 0.97 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL5053766 0.97 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1
SCHEMBL3406499 0.97 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2NR5A2NR5A1S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12226740-B2 Stabilized filtration device RETEIN AB (SE) 2025-02-18 — — US claimed
US-20220152559-A1 STABILIZED FILTRATION DEVICE RETEIN AB (SE) 2022-05-19 — — US claimed
CN-113453791-A Stabilized filter device 海纳有限公司 2021-09-28 — — CN claimed
US-20080160313-A1 Lipid bilayers on nanotextured solid surfaces ENERGY, U.S. DEPARTMENT OF 2008-07-03 — — US claimed
US-12263181-B2 Phospholipid compositions MACHAVERT PHARMACEUTICALS LLC (US) 2025-04-01 — — US disclosed
US-12226740-B2 Stabilized filtration device RETEIN AB (SE) 2025-02-18 — — US disclosed
CN-106456806-B Dual-purpose PAT/ultrasound contrast agent combined with drug-containing nanoparticles and preparation method thereof 艾姆戈特株式会社 2023-02-17 — — CN disclosed
US-20220409641-A1 PHOSPHOLIPID COMPOSITIONS MACHAVERT PHARMACEUTICALS LLC (US) 2022-12-29 — — US disclosed
US-11433085-B2 Phospholipid compositions MACHAVERT PHARMACEUTICALS, LLC (US) 2022-09-06 — — US disclosed
US-20220257620-A1 USE OF CERTAIN PHOSPHATIDYLCHOLINES CONTAINING LONG CHAIN POLYUNSATURATED FATTY ACIDS AS NEUROPROTECTIVE AGENTS KANNALIFE SCIENCES, INC. 2022-08-18 — — US disclosed
US-20220152559-A1 STABILIZED FILTRATION DEVICE RETEIN AB (SE) 2022-05-19 — — US disclosed
US-11079385-B2 Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis MED-LIFE DISCOVERIES LP (CA) 2021-08-03 — — US disclosed
US-20080160313-A1 Lipid bilayers on nanotextured solid surfaces ENERGY, U.S. DEPARTMENT OF 2008-07-03 — — US disclosed
EP-1761247-A1 INJECTABLE PHARMACEUTICAL SUSPENSION COMPRISING POSACONAZOLE SCHERING CORPORATION (US) 2007-03-14 — — EP disclosed
US-20060160823-A1 Particulate-stabilized injectable pharmaceutical compositions of Posaconazole SCHERING CORPORATION 2006-07-20 — — US disclosed
WO-2005117831-A1 INJECTABLE PHARMACEUTICAL SUSPENSION COMPRISING POSACONAZOLE SCHERING CORPORATION (US) 2005-12-15 — — WO disclosed
EP-0161519-B1 DERIVATIVES OF GLYCEROPHOSPHOCHOLINE AND OF GLYCEROPHOSPHOETHANOL AMINE, THEIR PREPARATION AND USE CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1988-06-29 — — EP disclosed
US-4717512-A Preparation of acylated glycerophosphocholines and glycerophosphoethanolamines CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1988-01-05 — — US disclosed
US-4622180-A Derivatives of glycerophosphocholine and glycerophosphoethanolamine, their preparation and their use CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1986-11-11 — — US disclosed
EP-0161519-A2 Derivatives of glycerophosphocholine and of glycerophosphoethanol amine, their preparation and use CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1985-11-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220409641-A1 PHOSPHOLIPID COMPOSITIONS PHOSPHO1, SGMS1, SGMS2 ALDH1A1 4849/4885SMN1; SMN2 1802/4885NR5A2 4657/4885
US-11433085-B2 Phospholipid compositions PHOSPHO1, SGMS1, SGMS2 ALDH1A1 4849/4885SMN1; SMN2 1802/4885NR5A2 4657/4885
US-20060160823-A1 Particulate-stabilized injectable pharmaceutical compositions of Posaconazole ERG28, CPSF7, CYP3A5 ALDH1A1 2131/4885SMN1; SMN2 3156/4885NR5A2 1678/4885
US-12263181-B2 Phospholipid compositions PHOSPHO1, SGMS1, SGMS2 ALDH1A1 4849/4885SMN1; SMN2 1802/4885NR5A2 4657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.